Tamoxifen debate hinges on whose risk is high enough.
作者信息
Reynolds T
出版信息
J Natl Cancer Inst. 1998 Oct 7;90(19):1428-30. doi: 10.1093/jnci/90.19.1428.
PMID:9776407
Abstract
摘要
相似文献
1
Tamoxifen debate hinges on whose risk is high enough.
J Natl Cancer Inst. 1998 Oct 7;90(19):1428-30. doi: 10.1093/jnci/90.19.1428.
2
Anti-estrogens come of age: a pioneer looks back.
J Natl Cancer Inst. 1998 May 6;90(9):646-7. doi: 10.1093/jnci/90.9.646.
3
Breast cancer biology blossoms in the clinic.
Nat Med. 1998 Jul;4(7):761-2. doi: 10.1038/nm0798-761.
4
Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
J Natl Cancer Inst. 1996 Aug 21;88(16):1100-2. doi: 10.1093/jnci/88.16.1100.
5
Status of antiestrogen breast cancer prevention trials.
Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):28-31.
6
Gynaecological aspects of tamoxifen treatment in breast cancer patients.
Cancer Treat Rev. 1997 Sep-Nov;23(5-6):289-304. doi: 10.1016/s0305-7372(97)90029-3.
7
[Tamoxifen and breast cancer: is everything known already?].
Tumori. 1998 Nov-Dec;84(6):A1-5.
8
Tamoxifen.
Nurs Times. 2006;102(8):33.
9
Tamoxifen and menopausal status: risks and benefits.
Lancet. 1996 Mar 16;347(9003):761. doi: 10.1016/s0140-6736(96)90111-7.
10
Tamoxifen therapy--long-term results and complications.
Adv Surg. 1996;29:263-9.
引用本文的文献
1
Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.
Ann Fam Med. 2005 May-Jun;3(3):242-7. doi: 10.1370/afm.284.
Zotero 插件